Head-to-head evidence
Bictegravir vs VH4524184
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Bictegravir · Biktarvy
Marketed by Gilead Sciences
NCT02607956 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.
Next expected readout: December 2026 · NCT06830668 (registry estimate)
VH4524184
Developed by ViiV Healthcare
NCT06214052 · Phase 2 · completed
The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported.
Next expected readout: June 2027 · NCT07202546 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir's landscape · VH4524184's landscape